Modelling and understanding powder flow properties and compactability of selected active pharmaceutical ingredients, excipients and physical mixtures from critical material properties
posted on 2017-11-01, 16:09authored byZelalem Ayenew Worku, Dinesh Kumar, João Victor Gomes, Yunliang He, Brian Glennon, Kiran A. Ramisetty, Åke C. Rasmuson, Peter O'Connell, Kieran H Gallagher, Trevor Woods, Nalini R Shastri, Anne-Marie Helay
The development of solid dosage forms and manufacturing processes are governed by complex
physical properties of the powder and the type of pharmaceutical unit operation the
manufacturing processes employs. Suitable powder flow properties and compactability are
crucial bulk level properties for tablet manufacturing by direct compression. It is also generally
agreed that small scale powder flow measurements can be useful to predict large scale
production failure. In this study, predictive multilinear regression models were effectively
developed from critical material properties to estimate static powder flow parameters from
particle size distribution data for a single component and for binary systems. A multilinear
regression model, which was successfully developed for ibuprofen, also efficiently predicted
the powder flow properties for a range of batches of two other active pharmaceutical
ingredients processed by the same manufacturing route. The particle size distribution also
affected the compactability of ibuprofen, and the scope of this work will be extended to the
development of predictive multivariate models for compactability, in a similar manner to the
approach successfully applied to flow properties.
History
Publication
International Journal of Pharmaceutics;531 (1), pp. 191-204
Publisher
Elsevier
Note
peer-reviewed
Other Funding information
SFI
Rights
This is the author’s version of a work that was accepted for publication in International Journal of Pharmaceutics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in International Journal of Pharmaceutics, 531 (1), pp. 191-204, https://doi.org/10.1016/j.ijpharm.2017.08.063